CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova , a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, announced a strategic collaboration in artificial intelligence (AI).

Under the terms of the collaboration, Harbour BioMed and Evinova China will jointly apply AI and digital technologies to enhance the efficiency of innovative biologics development. Building on their own strengths, the two companies aim to build an open ecosystem for AI-driven drug R&D.

Dr. J

See Full Page